⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for L-Arginine Supplements in Treating Women Who Are Cancer Survivors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: L-Arginine Supplements in Treating Women Who Are Cancer Survivors

Official Title: A Randomized Study to Determine Whether ArginMax Improves the Sexual Function and Quality of Life in Female Cancer Survivors

Study ID: NCT00459134

Interventions

ArginMax
Placebo

Study Description

Brief Summary: RATIONALE: L-arginine supplements may improve the quality of life and sexual function in women who are cancer survivors. PURPOSE: This randomized clinical trial is studying an L-arginine supplement to see how well it works compared with a placebo in treating women who are cancer survivors.

Detailed Description: OBJECTIVES: Primary * Determine whether an L-arginine-based nutritional supplement (ArginMax®) improves the quality of life and sexual function in female cancer survivors. Secondary * Compare quality of life of patients treated with ArginMax® vs placebo. * Compare toxicity of these regimens in these patients. * Describe the sexual function symptom clusters (if any) in these patients. OUTLINE: This is a randomized, double-blind, parallel-group, placebo-controlled, multicenter study. Patients are stratified according to ECOG performance status (0 or 1 vs 2 or 3), type of malignancy (pelvic vs nonpelvic), and ovarian functional status (yes vs no). Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive an oral L-arginine-based nutritional supplement (ArginMax®) twice daily. * Arm II: Patients receive oral placebo twice daily. In both arms, treatment continues for 12 weeks in the absence of unacceptable toxicity. Sexual function, quality of life, and toxicity are assessed at baseline and every 4 weeks for 12 weeks. PROJECTED ACCRUAL: A total of 186 patients will be accrued for this study.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

CCOP - Christiana Care Health Services, Newark, Delaware, United States

CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States

MBCCOP - Medical College of Georgia Cancer Center, Augusta, Georgia, United States

MBCCOP - JHS Hospital of Cook County, Chicago, Illinois, United States

CCOP - Central Illinois, Decatur, Illinois, United States

CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States

Cedar Rapids Oncology Associates, Cedar Rapids, Iowa, United States

MBCCOP - LSU Health Sciences Center, New Orleans, Louisiana, United States

Feist-Weiller Cancer Center at Louisiana State University Health Sciences, Shreveport, Louisiana, United States

CCOP - Michigan Cancer Research Consortium, Ann Arbor, Michigan, United States

CCOP - Beaumont, Royal Oak, Michigan, United States

CCOP - Heartland Research Consortium, Saint Louis, Missouri, United States

CCOP - St. Louis-Cape Girardeau, Saint Louis, Missouri, United States

CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States

Hematology Oncology Associates of Central New York, PC - Northeast Center, East Syracuse, New York, United States

CCOP - North Shore University Hospital, Manhasset, New York, United States

Alamance Cancer Center at Alamance Regional Medical Center, Burlington, North Carolina, United States

Hugh Chatham Memorial Hospital, Elkin, North Carolina, United States

Southeastern Medical Oncology Center - Goldsboro, Goldsboro, North Carolina, United States

Caldwell Memorial Hospital, Lenoir, North Carolina, United States

Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

CCOP - Columbus, Columbus, Ohio, United States

CCOP - Main Line Health, Wynnewood, Pennsylvania, United States

CCOP - Upstate Carolina, Spartanburg, South Carolina, United States

CCOP - Sioux Community Cancer Consortium, Sioux Falls, South Dakota, United States

Contact Details

Name: Kathryn M. Greven, MD

Affiliation: Wake Forest University Health Sciences

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: